2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2808 Clinical characteristics of long-term progression-free survivors following standard-of-care BCMA-directed CAR T-cell therapies for relapsed/refractory multiple myeloma

Brandon Kale, MD, Ariel Grajales-Cruz, MD2, Brandon Blue, MD3, Gabriel De Avila4, David Scheiber-Camoretti5, Ken Harada6, Daniel Deavila, MS7, Rebecca Gonzalez, PharmD8, Lauren C Peres, PhD, MPH9, Kristy Matte, PA-C10, Todd Stinard11, Blanca Lopez12, Marian Dam13, Laura B. Oswald, PhD14, Alicia Richards, PHD, MS15, Lucas Lee16, Zhuoer Xie, MD,MS17, Aleksandr Lazaryan, MD MPH PhD18, Joseph Pidala I, MD19, Ariosto Siqueira Silva, PhD20, Fabiana Perna, MD, PhD21, Hien Liu, MD22, Taiga Nishihori, MD23, Melissa Alsina, MD24, Rachid Baz, MD25, Kenneth H. Shain, MD, PhD26, Frederick L. Locke, MD27, Ciara Louise L Freeman, MD, PhD28, Omar Alexis Castaneda Puglianini, MD29, Doris K. Hansen, MD30
1 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
2 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
3 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
4 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
5 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
6 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
7 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
8 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
9 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
10 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
11 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
12 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
13 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
14 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
15 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
16 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
17 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
18 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
19 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
20 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
21 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
22 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
23 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
24 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
25 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
26 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
27 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
28 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
29 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
30 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Introduction: Although B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy (CAR-T) has demonstrated unprecedented efficacy in relapsed or refractory multiple myeloma (RRMM), factors associated with long-term disease control remain poorly defined. Here, we evaluate long-term (≥3 years) progression-free (PFS) and overall survival (OS), and clinical factors associated with durable disease control following standard-of-care (SOC) BCMA CAR-T for RRMM.

Methods: We retrospectively evaluated RRMM patients (n=195) treated with SOC BCMA CAR-T, idecabtagene vicleucel (148) and ciltacabtagene autoleucel (cilta-cel, 47), at Moffitt Cancer Center from 5/2021–5/2023. Patients remaining progression-free for ≥3 years (PF3Y) were compared with those progressing within 3 years. Baseline characteristics, treatment toxicities, and response outcomes were compared using Fisher’s exact and Wilcoxon rank-sum tests. PFS and OS were estimated using the Kaplan-Meier method. Median follow up was estimated using reverse Kaplan-Meier method. Univariable and multivariable Cox regression models using a landmark approach at day 90 after CAR-T infusion identified factors independently associated with PFS and OS. High-risk cytogenetics were defined per IMS-IMWG consensus criteria. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded by ASTCT consensus criteria.

Results: Median age was 66 years (range 38-88), and patients had received a median of 6 prior lines of therapy (range 3-13). High-risk cytogenetics, extramedullary disease, penta-drug refractoriness, and prior BCMA exposure were present in 48%, 16%, 27%, and 12% of patients, respectively. With a median follow-up of 40 months (range 0-59), median PFS was 15 months, and median OS was not reached. Estimated 36-month PFS was 30.3% and OS was 63%.

Among 195 infused patients, 181 were evaluable for 3-year PFS status; 8 died and 6 were lost to follow-up before reaching 3 years without prior progression. Of the 181 patients, 54 (29%) remained progression-free for at least 3 years. Compared with patients progressing before 3 years, PF3Y patients had lower rates of high-risk cytogenetics (30% vs. 56%, p=0.002), penta-class refractoriness (17% vs 31%, p=0.05), were more likely to have received cilta-cel (39% vs 17%, p=0.002), and were less likely to have received bridging therapy (54% vs. 70%, p=0.04). Other baseline characteristics including age, sex, race/ethnicity, prior lines of therapy, prior transplant, prior BCMA exposure, performance status, extramedullary disease, and marrow burden were similar.

PF3Y patients had higher rates of grade 2-4 CRS (33% vs 16%, p=0.01), and lower rates of grade 3 anemia at day 30 (4% vs 20%, p=0.009), whereas rates of ICANS, delayed neurotoxicities, infections, corticosteroid, tocilizumab or anakinra use, and intensive care unit admission were comparable between groups. PF3Y patients were more likely to achieve minimal residual disease (MRD) negativity by next-generation sequencing at any timepoint (90% vs 54%, p<0.0001), to sustain MRD negativity from day 90 to 1 year post CAR-T infusion (94% vs 36%, p=<0.0001), and to achieve a complete response (CR/sCR) (96% vs 61%, p<0.0001) and at least a very good partial response (≥VGPR) (98% vs 70%, p<0.0001).

On multivariable analyses, cilta-cel (HR 0.3, CI 0.2-0.7, p=0.002), grade 2-4 CRS (HR 0.4, CI 0.1-0.7, p=0.005), and day 90 MRD negativity (HR 0.4, CI 0.2-0.7, p=0.003) were independently associated with improved PFS, whereas penta-drug refractoriness (HR 1.9, CI 1.1-3.3, p=0.03), high-risk cytogenetics (HR 2.2, CI 1.3-3.9, p=0.004), and day 30 grade 3 anemia (HR 3.2, CI 1.2-8.0, p=0.02) were associated with inferior PFS. Prior BCMA exposure was independently associated with worse OS (HR 2.2, CI 1.1-4.1, p=0.03).

Conclusion: Nearly one-third of this heavily pretreated SOC BCMA CAR-T cohort remained progression-free for at least 3 years. Durable disease control was associated with cilta-cel therapy and characterized by favorable disease biology, robust CAR-T activity, and deep treatment responses. Our real-world findings align with published long-term trial data and inform prognostication, risk stratification, and post-CAR-T management.

Brandon Kale, MD: No relevant conflicts of interest to declare.